| Bioactivity | LM11A-31, a non-peptide p75NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression[1][2]. |
| In Vivo | LM11A-31 (口服灌胃；50 mg/kg/天，持续4周) 显著减轻了前神经生长因子proNGF的积累，并保持了血脑屏障的完整性[1]。LM11A-31 (口服；50或75 mg/kg) 在6-8个月龄开始，持续3个月的给药，能防止和/或逆转中期雄性APPL/S小鼠基底前脑胆碱能神经突起和皮层退化性神经突起的萎缩[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 102562-74-3 |
| Formula | C12H25N3O2 |
| Molar Mass | 243.35 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Elshaer SL, et al. Modulation of the p75 neurotrophin receptor using LM11A-31 prevents diabetes-induced retinalvascular permeability in mice via inhibition of inflammation and the RhoA kinase pathway. Diabetologia. 2019 Aug;62(8):1488-1500. [2]. Simmons DA, et al. A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. PLoS One. 2014 Aug 25;9(8):e102136. |